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Abstract There is still a lack in the molecular compre-
hension of major depressive disorder (MDD) although this
condition affects approximately 10% of the world popu-
lation. Protein phosphorylation is a posttranslational mod-
ification that regulates approximately one-third of the
human proteins involved in a range of cellular and bio-
logical processes such as cellular signaling. Whereas
phosphoproteome studies have been carried out extensively
in cancer research, few such investigations have been
carried out in studies of psychiatric disorders. Here, we
present a comparative phosphoproteome analysis of post-
mortem dorsolateral prefrontal cortex tissues from 24 MDD
patients and 12 control donors. Tissue extracts were ana-
lyzed using liquid chromatography mass spectrometry in a
data-independent manner (LC-MSE). Our analyses resulted
in the identification of 5,195 phosphopeptides, corre-
sponding to 802 non-redundant proteins. Ninety of these
proteins showed differential levels of phosphorylation in
tissues from MDD subjects compared to controls, being 20
differentially phosphorylated in at least 2 peptides. The
majority of these phosphorylated proteins were associated
with synaptic transmission and cellular architecture not
only pointing out potential biomarker candidates but mainly
shedding light to the comprehension of MDD pathobiology.
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Introduction
Major depressive disorder (MDD) is characterized by
feelings of low mood and self-esteem and by loss of interest
or pleasure in activities [12]. The consequences of MDD
include negative effects on work and social relationships
and associated comorbidities such as substance abuse and
anxiety, which results in an enormous financial burden on
healthcare services. The combination of direct costs, mor-
tality costs arising from depression-related suicides and
costs associated with effects on the workplace were esti-
mated to be over 80 billion dollars in the United States alone
in the year 2000 [14]. MDD is now thought to be a leading
cause of disability worldwide and has been hypothesized to
be the most incident disease of the twenty-first century [12].
Despite the fact that a number of molecular and image-
based studies have been performed, an understanding of the
underlying pathophysiology is still lacking, and there are
still no robust empirical means of increasing our ability to
diagnose such conditions accurately.
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The Human Proteome Organization (HUPO) emerged
from the Human Genome Project as a means of under-
standing gene and protein functions that may lead to the
understanding of diseases such as MDD and to the iden-
tification of diagnostic/prognostic biomarkers [44]. The
human genome is now known to contain approximately
35,000 genes [26, 58], although the number of proteins is
anticipated to be at least one order of the magnitude
greater. One reason for this high number is due to the fact
that proteins can undergo posttranslational modifications
such as phosphorylation [48], which can give rise to mul-
tiple forms of the same gene product.
Recent advances have been made in the development
and application of large-scale molecular profiling tech-
niques such as transcriptomics [43] and proteomics [4, 38,
39] in studies of biological tissues from MDD patients.
However, there have only been a few studies on differential
patterns of protein phosphorylation in MDD [38]. Phos-
phorylation controls a diverse range of cellular processes
such as cell signaling via switching mechanism of the
kinase-mediated addition of a high energy phosphate group
to a serine, threonine or tyrosine residue on a protein. The
large-scale analyses and quantification of phosphoproteins
and/or phosphopeptides using mass spectrometry are
known as phosphoproteomics and have been employed
mostly in studies of cancer [2, 10] and neurodegenerative
disorders studies [9, 15]. For instance, the hyperphosph-
orylation of TAU is one of the central mediators of Alz-
heimer’s disease (AD) pathogenesis. Studies of TAU
phosphorylation have proven to be an effective example of
how to discover molecular mechanisms and signaling
pathways involved in pathogenic processes in the brain.
Phosphoproteomics offer us the possibility of investigating
in a large-scale manner the functional role of proteins,
which is a subject mostly neglected in large-scale proteome
studies. Investigation of changes in the phosphorylation
states of proteins, which are independent of changes in
their total expression, can provide insights about molecular
signaling and mechanisms such as neuroplasticity and
synaptic transmission.
Here, we have carried out a differential phosphoproteo-
mic analysis of postmortem dorsolateral prefrontal cortex
(DLPFC) tissue from MDD patients (n = 24) compared to
matched controls (n = 12) using liquid chromatography
mass spectrometry in a data-independent mode (LC-MSE).
Our interest in the DLPFC arises from the important role that
this brain structure plays inMDDpathogenesis [24]. It was of
particular importance to determine whether differential
phosphorylation is involved in the pathogenesis of MDD
and whether such molecules might be used as potential
biomarker candidates [32] as a means of developing novel
molecular biomarker tests to improve diagnosis and for use
as surrogate biomarkers in drug discovery studies.
Methods and materials
Brain tissue samples
Postmortem DLPFC tissues (Brodmann area 9) from 24
MDD patients and 12 matched control subjects were
obtained from the Stanley Medical Research Institute brain
collection (Bethesda, MD, USA) (Table 1 and Supple-
mentary Material 1). Consent was obtained by question-
naire-based telephone interview and signed by the
interviewer and a witness. The Institutional Review Board
at the Uniformed Services University of Health Sciences
determined that the procedure was exempt from federal and
state regulations governing human research, since speci-
mens were obtained from cadavers and anonymized with
respect to personal information.
Sample preparation
Brain tissue samples (20 mg) were homogenized individ-
ually in 100 lL of 7 M urea, 2 M thiourea, 4% CHAPS,
2% ASB-14 and 70 mM DTT [40] using the Sample
Grinding Kit (GE Healthcare; Little Chalfont, Bucks, UK).
Samples were centrifuged for 10 min at 16,0009g. The
supernatants were collected and protein concentrations
determined using the Bradford dye-binding assay (Sigma;
Poole, Dorsett, UK).
Shotgun LC-MSE proteomics workflow
The following workflow was established previously [37].
Protein samples (15 lg) were subjected to sodium doce-
cylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)
for pre-fractionation to enhance phosphoproteome cover-
age. Protein bands were visualized using Coomassie blue
staining, and each lane containing stained protein bands
was sliced to produce 3 horizontal sections. Gel sections
were subjected to trypsin digestion in situ and resulting
peptide mixtures were lyophilized. The peptides were
suspended in 0.1% formic acid and injected (0.5 lg) in
duplicate into a nano Ultra Performance Liquid Chroma-
tography instrument containing a BEH-130 C18 column
(75 lm 9 200 mm) at a flow rate of 0.3 lL/min connected
online to a Q-TOF Premier Mass Spectrometer (Waters
Corporation; Manchester, UK). Eluted peptides were
measured in MSE mode (data-independent analysis) using
the ion accounting algorithm [28] for data processing.
Analysis of the resulting chromatograms/mass spectra and
database searching were performed using the ProteinLynx
Global Server (PLGS) v.2.4 (Waters Corp.). Quantitative
and statistical analyses were performed using the Rosetta
Elucidator system v.3.3.0.1.SP3.19 (Rosetta Inpharmat-
ics; Seattle, WA, USA).
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Statistical analyses
Wilcoxon signed-rank test was used to determine signifi-
cant differences between the groups under comparison
(p\ 0.05) in case data are not normally distributed. False
discovery rate (FDR) was calculated according to Benja-
mini and Hochberg [5]. No adjustments were made for
multiple comparisons as previously supported [53]. This
approach is to avoid the exclusion of possible true positives
since proteomic data are not necessarily random but can be
physiologically interdependent observations, even though a
Q-value threshold of approximately 0.4 and a fold change
cut off of 10% have been established.
Considering that MDD and controls groups are matched
for demographic variables (Table 1), results here are unlike
to have suffered influence of gender, age, alcohol abuse,
smoking, postmortem interval and refrigeration interval.
By using principal component analysis (PCA), we could
observe that potential interferences of medication are also
unlikely (Supplementary Material 1).
Phosphoproteome analyses
Potential phosphorylated molecules were identified auto-
matically by PLGS based on the experimentally deter-
mined loss of a 80 Da PO3- ion from peptides containing
one or more phosphorylation consensus sequences featur-
ing serine, threonine or tyrosine residues. Quantification
was performed using the Elucidator system.
Western blot validation
Brain tissue samples were prepared as described above.
Samples were arranged in randomized order such that each
of the two diagnostic groups (Controls vs. MDD) was
represented on each gel. For each sample, 40 lg of total
protein was electrophoresed using pre-cast Novex 10–20%
Tricine polyacrylamide gels (Invitrogen; Paisley, UK) at
150 V for about 60 min, followed by semidry electropho-
retic transfer to Immobilon-FL polyvinyldiphenyl fluoride
(PVDF) membranes (Millipore; Watford, UK). The mem-
branes were incubated in a 1:1 mixture of Odyssey
blocking buffer (Li-COR Biosciences; Cambridge, UK).
Membranes were then incubated overnight at 4C with
anti-Dynamin 1 (phospho S774) antibody (ab55324) at
1/500 dilutions (Abcam; Cambridge, UK). The membranes
were washed in Tris-buffered saline (TBS) containing
0.1% Tween-20 for 1 h at room temperature (4 9 20 min)
and then incubated for 1 h at room temperature with the
appropriate IR-dye-conjugated secondary antibodies
(1:7,500 for secondary rabbit antibody Li-COR Biosci-
ences) in blocking buffer. Immunoreactive protein bands
were visualized using the Odyssey Infra-red imaging sys-
tem (Li-COR Biosciences) and the integrated intensities
(II) of the bands measured. Values which lay outside the
mean by more than twice the standard deviation were
excluded from the analysis.
Biological classification
Differentially phosphorylated proteins in MDD DLPFC
were classified according to their biological pathways and
subcellular localization using the Human Protein Reference
Database (http://www.hprd.org). For interpreting func-
tional significance of differentially phosphorylated pro-
teins, the associated SwissProt accession identification
codes for each phosphoprotein were uploaded into the
Ingenuity Pathways Knowledge Base (IPKB) (http://www.
ingenuity.com), and these were analyzed to identify
potential interactions between these proteins and other
proteins in the IPKB and for determining the most signif-
icant biological, disease and canonical pathways associated
with these proteins (significance determine using Fisher’s
exact test).
Results
Using our shotgun LC-MSE approach, we could identify
5,195 phosphopeptides in all the 36 analyzed samples
corresponding to 802 distinct proteins. Comparing MDD
patient samples to controls, significant differences in
phosphorylation levels (p\ 0.05—Wilcoxon signed-rank
test) were observed for 116 phosphopeptides, correspond-
ing to 90 distinct proteins (Table 2). Ten of these proteins
(11.1%—Table 2 in black) were found with differences in
protein expression, which impairs the confirmation of their
differential phosphorylation. Fifty-three proteins (58.9%)
presented phosphorylation differences in one phosphory-
lation site in a single peptide, while 17 proteins (18.9%)
presented phosphorylation differences in at least 2
Table 1 Demographic information for the samples used in the study
(mean ± SD)
Control MDD Significance
t test (p)
Sample size 12 24
Age 47 ± 12 42 ± 11 0.38
Postmortem interval 25.3 ± 10.6 29.7 ± 12.4 0.44
Refrigerator interval 7.4 ± 5.4 7.9 ± 6.3 0.80
Brain pH 6.6 ± 0.2 6.7 ± 0.2 0.44
Fisher’s exact
Gender (male/female) 8/4 13/11 0.57
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Table 2 Differentially
phosphorylated peptides
identified and their
correspondent proteins
In black, proteins found with
differences in expression (42).
In gray, proteins found
differentially phosphorylated in
more than 1 peptide
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phosphorylation sites in a single peptide. More consis-
tently, 20 proteins (22.2%) were differentially phosphory-
lated in more than 1 peptide (Table 2 in gray). For 3 of
them—alpha-crystallin B chain (CRYAB), 60 kDa heat
shock protein, mitochondrial (HSPD1) and myelin basic
protein (MBP)—phosphopeptides presented phosphoryla-
tion differences in opposite directions. The presented
results are not likely to have suffered neither interference
of demographics (Table 1) nor medication according to a
PCA which did not show clustering of samples (Supple-
mentary material 1).
These phosphoproteins were assigned according to
their biological processes in order to comprehend the
biochemical pathways associated with the differential
phosphorylation signaling (Fig. 1). Seven different bio-
logical processes were represented, being ‘‘cell growth
and maintenance’’ the most frequent class (Fig. 1a). Dif-
ferentially phosphorylated proteins were also classified
according to their cellular localization (Fig. 1b). Although
most of them are cytoplasmic (56%), there was a signif-
icant coverage of membrane proteins (30%), which are
important targets not only for protein signaling, but for
potential drug targets. Phosphoproteins were also sub-
mitted to a systems biology analyses in IPKB as to be
discussed ahead (Fig. 2). Considering the large-scale
nature of our analyses, we performed a Western blot
Fig. 1 a Biological function
and b cellular localization of the
differentially phosphorylated
proteins in MDD brains
Fig. 2 Network of proteins
interactions among the
differentially phosphorylated
proteins according to systems
biology analyses by ingenuity
pathways knowledge base
Eur Arch Psychiatry Clin Neurosci (2012) 262:657–666 661
123
validation of phosphorylated Dynamin 1, confirming the
LC-MSE findings (Fig. 3).
Discussion
Despite their obvious importance, there is still a lack about
phosphoproteomic studies in psychiatric disorders [38]. It
is estimated that protein phosphorylation regulates
approximately one-third of the human proteins in a wide
range of cellular processes [59]. Moreover, phosphoprote-
omic analyses could provide information about phosphor-
ylation status, increasing the understanding about the
functional aspects of the MDD. Even not using any special
preparation for this purpose, we evaluate the phosphopro-
teomic differences in MDD compared to controls. We
focused our discussion and our illustrations in the 20 pro-
teins that showed differences in phosphorylation in at least
2 peptides, since those provide more confidence regarding
differential phosphorylation. Nevertheless, the remaining
70 proteins are also important protein targets to be con-
sidered, proved by the fact that they fit in a biological and
molecular context as further presented.
The identification of differential phosphorylation in sub-
units of clathrin (CLTCandCLTCL1), spectrin (SPTBN1 and
SPTBN2) and synapsin (SYN1) as well as the identification
and validation of dynamin (DNM1) (Fig. 3) reinforces the
impairment of synaptic transmission in MDD [16]. As rep-
resented in Fig. 4, our phosphoproteomic findings suggest a
generalized dysregulation of the cytoskeleton signaling,
which may compromise cell morphology and synaptic trans-
mission. SPTBN1 and SPTBN2 together with other spectrin
subunits like spectrin alpha chain (SPTAN1) are responsible
for connecting plasma membrane to the actin cytoskeleton,
playing roles in cell morphology, organelles organization and
transmembrane proteins arrangement [6]. Alpha-actinin-4
(ACTN4) also belongs to the spectrin superfamily playing
complementary roles to SPTBN1 and SPTBN2 and has been
implicated in central nervous system (CNS) disorders such as
schizophrenia and epilepsy [46]. Beta-adducin (ADD2) also
plays structural roles in binding and regulating actin and
spectrin filaments and contains phosphorylation sites for
protein kinase C and calmodulin binding site [7]. Interest-
ingly, Add2 KOmice presented differences in expression and
phosphorylation levels of alpha- and gamma-adducin as well
as impairments in synaptic plasticity, motor coordination,
behavioral and learning deficits [51]. In addition, mRNA of
sodium potassium transporting subunit alpha-3 (ATP1A3),
calcium calmodulin dependent protein kinase type II alpha
chain (CAMK2A) and vimentin (VIM) were found differen-
tially expressed in MDD DLPFC [57].
Microtubule-associated proteins (MAPs) such as
MAP1B and MAP2, which we found differentially phos-
phorylated in MDD DLPFC, bind to tubulin subunits for
regulating microtubules assembly and stability. These are
necessary for several cellular processes in brain tissue such
as axonogenesis and dendritogenesis during neurodevel-
opment and function [1] as supported by studies in MAP1B
null mice [8]. Moreover, MAP2 acts stabilizing and shap-
ing dendrites during neuron development [13]. Interest-
ingly, we found MAP1B less phosphorylated in MDD
brain, in line with previous functional studies which sug-
gested that a dephosphorylated state of MAP1B may trig-
ger cytoskeletal alterations that will impair long-term
potentiation leading ultimately to impaired synaptic plas-
ticity [62]. In addition, MAP1B null adult mice presented
alterations in myelin sheath diameter as well as conduc-
tance velocity of peripheral axons in the corpus callosum,
which is in line with the differential phosphorylation we
found for MBP in MDD DLPFC [8]. Stress-unsusceptible
rats from a chronic social defeat stress model presented
lower levels of Map1b mRNA in the frontal cortex and
hippocampus [20]. Although we did not find significant
differences in proteins expression when comparing MDD
and control subjects, the reduced gene expression in the
social defeat model and differential protein phosphoryla-
tion in brain tissue reinforce the role of MAP1B in the
impairment of the synaptic transmission in MDD. More-
over, the inhibition of GSK-3beta by lithium leads to the
loss of phosphorylated MAP-1B and thus to axonal
remodeling [30], suggesting MAP1B as a potential drug
target.
Fig. 3 Validation of Dynamin 1 as a candidate of differentially
phosphorylated protein in the DLPFC from MDD patients and
controls. p values were obtained by Student’s t-test statistical analysis
662 Eur Arch Psychiatry Clin Neurosci (2012) 262:657–666
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MAP1B is also involved in growth cone and axonal
activity [45] so as alpha-internexin (INA) and dihy-
dropyrimidinase-related protein 2 (DPYSL2). INA, which
is also present in dendrites, is one of the responsible pro-
teins to maintain neuronal caliber and is involved in neu-
ronal morphogenesis together with neurofilaments L, M
(NEFL and NEFM) [11], which we also found differen-
tially phosphorylated. DPYSL2, which acts in the regula-
tion of axon guidance, vesicle trafficking and synaptic
function, has been shown to bind and be modulated by
antidepressants and neuroactive molecules [19]. INA and
DPYSL2 have been found differentially expressed in
schizophrenia brains [34, 35, 41]. While their phosphory-
lation status has not been mentioned on schizophrenia,
differences in expression of these proteins have not been
related to MDD so far.
Synapsin-1 (SYN1) is a neuronal membrane phospho-
protein that anchors to synaptic vesicles which is involved
in axogenesis, synaptogenesis and modulation of neuro-
transmitter release [56] so as N-ethylmaleimide-sensitive
fusion protein (NSF), which is a key synaptic component
especially in synaptic transmission SNARE-mediated [60].
SYN1 has been implicated in psychiatric disorders and
could be a target for their treatment [61]. Synaptic vesicles
reserved in the axon are converted to ready-to-release
vesicles depending on SYN1 phosphorylation. When pre-
synaptic membranes depolarize, there is a calcium influx
into the axonal nerve, which can involve plasma membrane
calcium-transporting ATPase 3 (ATP2B3) that we also
found to be differentially phosphorylated. Calcium ions
bind to calmodulin, and the complex calcium/calmodulin
activates protein kinases that phosphorylate SYN1. In turn,
SYN1 dissociates from the vesicle membrane, leading it for
release [25, 54] (Fig. 4). Interestingly, SYN1 interacts with
amphiphysin (AMPH) [47], which we found to be differ-
entially expressed in MDD brains [36].
When ready-to-release synaptic vesicles reach the axo-
nal membrane, they are mechanically involved by dyna-
mins like DNM1, DNM2 and DNM3, which forms a spiral
around the vesicle forcing their rupture at the expense of
GTP hydrolysis [18] (Fig. 4). Interestingly, differences in
the phsophorylation levels of clathrin heavy chain 1 and 2
(CLTC and CLTCL1) were also observed in MDD DLPFC.
Clathrin complex performs a pivotal role in shaping
synaptic vesicles and can be recycled after vesicle cycles
also playing roles in axon guidance and organization of
cellular membrane [29]. The roles of DNM1 and CLTC as
well as the pivotal role of NSF can be observed in
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Fig. 4 Integrated view of the role players of the synaptic dysfunction in MDD brains. Colored proteins were found differentially phosphorylated
between MDD patients versus controls
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http://stke.sciencemag.org/content/vol2004/issue264/images/
data/re19/DC2/slowtrack2.swf. Differences in the phos-
phorylation levels of key proteins such as DNM1 and
CLTC can impair significantly synaptic transmission.
Although synaptic transmission is a known mechanism
in MDD, revealing exactly which proteins, peptides and
amino acids are differentially phosphorylated can lead to
potential targets for therapeutic studies, paving way to the
discovery of new drugs.
MBP, which is the major structural component of the
myelin sheets in the CNS, and alpha-crystallin B (CRYAB)
were identified with differential phosphorylation by two
peptides, being one more phosphorylated and the other less
phosphorylated. MBP gene and protein expression have
been found altered consistently in schizophrenia [1, 31, 33,
42] and multiple sclerosis [55]. In addition, the differential
expression of MBP in the entorhinal cortex in schizo-
phrenia patients correlates to migrational disturbances of
pre-alpha cell clusters leading to deficits in axonal myeli-
nation and disturbed connectivity during neurodevelop-
ment [49]. CRYAB was also previously found
differentially expressed in schizophrenia [41]. Therefore,
the differential phosphorylation of MBP and CRYAB
protein modification cannot point out a process specific for
MDD, but can indicate trait processes of neuropsychiatric
disorders. Considering the structural role of these proteins
added to the cytoskeleton impairment described above, we
here present the possible players of the impaired cytoar-
chitecture of MDD brain tissue. Recently, there has been
found a correlation between the phosphorylation of CRY-
AB with apoptosis in breast cancer cells [27]. In addition,
CRYAB acts as molecular chaperone [50], and the differ-
ential phosphorylation of other 3 heat shock proteins here
found—putative heat shock protein HSP 90-beta-3
(HSP90AB3P), putative heat shock protein HSP 90-alpha
A2 (HSP90AA2) and 60 kDa heat shock protein, mito-
chondrial (HSPD1)—may suggest impaired cellular envi-
ronment. Interestingly, CRYAB has an autokinase activity,
and posttranslational modifications decrease their role as
chaperone [21].
Energy metabolism pathways have been associated
intimately with MDD [3, 22, 52]. In line with these results,
we observed recently that several oxidative phosphoryla-
tion enzymes were differentially expressed in MDD [36].
We found differences in the phosphorylation levels of
metabolic enzymes such as aconitate hydratase (ACO2),
enolase (ENO2 and ENO3), hexokinase-2 (HK2) and
L-lactate dehydrogenase A (LDHA).
As for any postmortem brain tissue research, some
potential limitations of our study have to be addressed.
Factors such as age, gender, postmortem interval and oth-
ers may confound global proteomic analyses especially in
postmortem studies [23]. However, these factors are
unlikely to have had significant effects on our analyses,
considering that the compared groups are matched for
demographic variables and these have not shown signifi-
cant differences (Table 1). In addition, no segregation of
subjects has been observed using principle component
analyses for medication effects (Supplementary material
1). The limited sample sizes can also be a drawback in
postmortem brain tissue studies, suggesting, therefore,
replication in an independent sample cohort. In addition, it
is suggested validation in a larger number of samples for
overcoming errors from multiple testing. Even with all
potential drawbacks, we believe that the analysis of post-
mortem tissue from patients while studying brain disorders
is indispensable as reported recently [17]. These studies
have generated insights for psychiatric studies that have
been useful in basic and applied research.
Interestingly, the differences in phosphorylation that we
observed in MDD DLPFC brain tissue can be connected in
a net of interactions and roles as described in Figs. 2 and 4.
The advantage of a hypothesis-free analysis as we per-
formed is to give the opportunity to reveal the real players
of the studied disorder. Moreover, considering the signal-
ing role of phosphorylation, which is indispensable for
cellular structure, neuroplasticity and communication, the
protein candidates presented here be considered therapeutic
targets to be further explored in drug response and drug
discovery studies.
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